Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) EBITDA Margin: 2016-2024

Historic EBITDA Margin for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to -43.33%.

  • Akebia Therapeutics' EBITDA Margin rose 5446.00% to 0.92% in Q3 2025 from the same period last year, while for Sep 2025 it was -7.07%, marking a year-over-year decrease of 31900.00%. This contributed to the annual value of -43.33% for FY2024, which is 47592.00% up from last year.
  • Akebia Therapeutics' EBITDA Margin amounted to -43.33% in FY2024, which was up 91.65% from -519.25% recorded in FY2023.
  • Akebia Therapeutics' EBITDA Margin's 5-year high stood at -32.22% during FY2022, with a 5-year trough of -519.25% in FY2023.
  • In the last 3 years, Akebia Therapeutics' EBITDA Margin had a median value of -43.33% in 2024 and averaged -198.27%.
  • As far as peak fluctuations go, Akebia Therapeutics' EBITDA Margin surged by 266,337bps in 2020, and later slumped by 48,703bps in 2023.
  • Over the past 5 years, Akebia Therapeutics' EBITDA Margin (Yearly) stood at -130.61% in 2020, then plummeted by 265bps to -133.25% in 2021, then soared by 10,104bps to -32.22% in 2022, then crashed by 48,703bps to -519.25% in 2023, then spiked by 47,592bps to -43.33% in 2024.